Related Experiment Video
Updated: Nov 23, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.5K
Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Takuya Yamashita1, Masaki Shiota1, Asako Machidori1
1Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Cancer Investigation
|January 4, 2021
Summary
A 4-weekly docetaxel regimen shows comparable efficacy and safety to the standard 3-weekly schedule for castration-resistant prostate cancer. This 4-weekly chemotherapy approach may be a viable option for select patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer.
- Docetaxel is a standard chemotherapy agent for CRPC, typically administered every 3 weeks.
Purpose of the Study:
- To evaluate the efficacy and safety of a 4-weekly docetaxel regimen compared to the standard 3-weekly regimen in Japanese men with CRPC.
Main Methods:
- Retrospective analysis of 125 Japanese male patients with CRPC treated between 2008 and 2018.
- Comparison of outcomes (progression, treatment failure, mortality) and severe adverse events between patients receiving 3-weekly and 4-weekly docetaxel regimens (median dose 70 mg/m²).
Main Results:
- The 4-weekly docetaxel regimen demonstrated comparable risks of progression, treatment failure, and all-cause mortality to the 3-weekly regimen.
- Incidences of severe adverse events were similar between the two dosing schedules.
Conclusions:
- The 4-weekly docetaxel regimen is a safe and effective alternative for selected patients with castration-resistant prostate cancer.
- This dosing schedule offers a comparable risk profile to the standard 3-weekly administration.
